Investigational drug · Phase 3
Rulonilimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cervical Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Jan 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "Rulonilimab"
First trial start
2024
Sep 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rulonilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cervical Cancer
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Rulonilimab" as an intervention, largest first.
- the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaPivotal-lookingStatus unknown
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT05408221 · 576 participants (planned) · Start Nov 11, 2022 · Primary completion Aug 1, 2025
Drug: Rulonilimab+Lenvatinib; Rulonilimab placebo +Lenvatinib · For: Hepatocellular Carcinoma
Sites: Beijing, China; Guandong, China; Shandong, China · 5 sites in all
- A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerPivotal-lookingEnrolling by invitation
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT06755515 · 510 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 2028
Drug: Rulonilimab; Placebo and 1 more · For: Cervical Cancer
Sites: Linyi, China
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT05741021 · 84 participants (planned) · Start Mar 1, 2023 · Primary completion Oct 25, 2024
Drug: F520; Pemetrexed and 2 more · For: Non-small Cell Lung Cancer; NSCLC; PD-1
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cervical Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.